Topicalandrogenreceptorantagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topicalandrogenantagonist could potentially enhance treatment, but oral use of androgenantagonists is too risky due to severe side effects.
The conversation discusses topicalandrogenreceptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
Researching and developing an effective local antagonist to block the androgenreceptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.
The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgenreceptorantagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.
The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topicalandrogenreceptorantagonist like RU58841.